Cited by 474Alzheimer's disease research and treatmentsDementia and Cognitive Impairment ResearchMedical Imaging Techniques and Applications

An autoradiographic evaluation of AV-1451 Tau PET in dementia

Open access
Lowe, Val J., Curran, Geoffry, Fang, Ping, Liesinger, Amanda M., Josephs, Keith A., Parisi, Joseph E., Kantarci, Kejal, Boeve, Bradley F. +11 more·2016·Acta Neuropathologica Communications

Abstract

BACKGROUND: It is essential to determine the specificity of AV-1451 PET for tau in brain imaging by using pathological comparisons. We performed autoradiography in autopsy-confirmed Alzheimer disease and other neurodegenerative disorders to evaluate the specificity of AV-1451 binding for tau aggregates. METHODS: Tissue samples were selected that had a variety of dementia-related neuropathologies including Alzheimer disease, primary age-related tauopathy, tangle predominant dementia, non-Alzheimer disease tauopathies, frontotemporal dementia, parkinsonism, Lewy body disease and multiple system atrophy (n = 38). Brain tissue sections were stained for tau, TAR DNA-binding protein-43, and α-synuclein and compared to AV-1451 autoradiography on adjacent sections. RESULTS: AV-1451 preferentially localized to neurofibrillary tangles, with less binding to areas enriched in neuritic pathology and less mature tau. The strength of AV-1451 binding with respect to tau isoforms in various neurodegenerative disorders was: 3R + 4R tau (e.g., AD) > 3R tau (e.g., Pick disease) or 4R tau. Only minimal binding of AV-1451 to TAR DNA-binding protein-43 positive regions was detected. No binding of AV-1451 to α-synuclein was detected. "Off-target" binding was seen in vessels, iron-associated regions, substantia nigra, calcifications in the choroid plexus, and leptomeningeal melanin. CONCLUSIONS: Reduced AV-1451 binding in neuritic pathology compared to neurofibrillary tangles suggests that the maturity of tau pathology may affect AV-1451 binding and suggests complexity in AV-1451 binding. Poor association of AV-1451 with tauopathies that have preferential accumulation of either 4R tau or 3R tau suggests limited clinical utility in detecting these pathologies. In contrast, for disorders associated with 3R + 4R tau, such as Alzheimer disease, AV-1451 binds tau avidly but does not completely reflect the early stage tau progression suggested by Braak neurofibrillary tangle staging. AV-1451 binding to TAR DNA-binding protein-43 or TAR DNA-binding protein-43 positive regions can be weakly positive. Clinical use of AV-1451 will require a familiarity with distinct types of "off-target" binding.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s40478-016-0315-6

Cites

55 of 55 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Flortaucipir binds weakly or not at all to sole 4R or sole 3R tau deposits in primary tauopathies.

    “Flortaucipir binds weakly or not at all to sole 4R or sole 3R tau deposits in primary tauopathies [126–128].”
  • Previous post-mortem work has demonstrated some binding of 18F-AV-1451 to FTLD pathologies, albeit at a lower magnitude than that seen with Alzheimer's pathology.

    “Supporting our use of 18F-AV-1451 as a marker of non-amyloid-β protein aggregation, previous post-mortem work has demonstrated some binding to FTLD pathologies, albeit at a lower magnitude than that seen with Alzheimer’s pathology (Marquié et al., 2015; Lowe et al., 2016; Mcmillan et al., 2016; Sander et al., 2016).”
  • The molecular target in FTD associated with TDP43 is as yet undetermined, but is unlikely to be TDP43 itself.

    “The molecular target in FTD associated with TDP43 is also as yet undetermined, but is unlikely to be TDP43 itself (Marquié et al., 2015; Lowe et al., 2016; Sander et al., 2016).”
  • [18F]AV-1451 shows strong in vivo and post-mortem binding to tau pathology in Alzheimer's disease, but has variable affinity in healthy aging and non-AD tauopathies.

    “Although [18F]AV-1451 shows strong in vivo and post-mortem binding to tau pathology in AD, it displays variable affinity in healthy aging and non-AD tauopathies28–30.”
  • [18F]AV-1451 binds to non-tau proteinopathies and to other targets such as neuromelanin, choroid plexus, and monoamine oxidase.

    “The tracer also binds to non-tau proteinopathies (i.e., is positive in TDP43 pathology with C9orf72 mutations and semantic dementia31), and other targets such as neuromelanin29, choroid plexus28 and monoamine oxidase (MAO)32.”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 1

  1. [38]Xia CF Arteaga J Chen G Gangadharmath U Gomez LF Kasi D Lam C Liang Q Liu C Mocharla VP [(18)F]T807, a novel tau positron emission tomography imaging agent for Alzheimer’s disease Alzheimers Dement 2013 9 666 676 10.1016/j.jalz.2012.11.008 23411393 · DOI · Paper page

Cited by

Sorted by citations

Authors
Lowe, V. J., Curran, G., Fang, P., Liesinger, A. M., Josephs, K. A., Parisi, J. E., Kantarci, K., Boeve, B. F., Pandey, M. K., Bruinsma, T., Knopman, D. S., Jones, D. T., Petrucelli, L., Cook, C. N., Graff-Radford, N. R., Dickson, D. W., Petersen, R. C., Jack, C. R., & Murray, M. E.
Affiliations
Mayo Clinic (US)
Corresponding author
Lowe, Val J.
Venue
Acta Neuropathologica Communications
Published
2016-06-13
Volume
4
Issue
1
Pages
58-58
ISSN
2051-5960 (ISSN-L)
OpenAlex
W2426305809
Cited by
474
References
55
Citations by year
2026: 20 · 2025: 28 · 2024: 34 · 2023: 39 · 2022: 44 · 2021: 51 · 2020: 66 · 2019: 52 · 2018: 57 · 2017: 67 · 2016: 15
FWCI
51.27
Type
journal article
Language
en
Open access
Locations
  • Acta Neuropathologica Communications (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
  • National Institutes of Health (P50-AG016574, P50-NS072187)
  • National Institute on Aging (R01 NS89757, R01 DC10367)
Topics
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
Keywords
tau PET, neurofibrillary tangles, Alzheimer's disease, tauopathy, tau isoforms, off-target binding, alpha-synuclein, dementia, Braak staging, Pick's disease, Lewy body disease, multiple system atrophy, frontotemporal dementia, autoradiography
MeSH terms
Aged, Aged, 80 and over, Autoradiography, Brain, Carbolines, Dementia, DNA-Binding Proteins, Female, Humans, Male, Middle Aged, tau Proteins, Radiopharmaceuticals, Neurodegenerative Diseases, Protein Isoforms, Positron-Emission Tomography

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review